MDA-MB-361 breast adenocarcinoma cells treated in vitro with allosteric AKT inhibitor MK2206 until development of resistance.
Whole exome sequencing to determine whether acquisition of resistance to MK2206 in MDA-MB-361 is mediated by a new AKT1 mutation.  Cells were exposed in vitro to drug for 12 weeks.  Surviving cells were expanded for another 2 weeks in the presence of drug before sequencing.